Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V

Status
Status: Commission completed
Project no.
A25-95
Last updated

Report documents

  1. Extract of dossier assessment

    Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 354 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-95_en
    Download file : Extract of dossier assessment (PDF document, 354 kB, EN, not accessible)

  2. Dossier assessment

    Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 603 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-95
    Download file : Dossier assessment (PDF document, 603 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with progressive or recurrent active chronic inflammatory demyelinating polyneuropathy after previous treatment with corticosteroids or immunoglobulins

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A25-95
Commission
Commission awarded on 24.07.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-95_en

Connected Projects

  1. Dossier assessment

    Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-36
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Efgartigimod alfa (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G22-29
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page